Table 1.

Case series of resection of liver metastases in MBC published within the last 20 years

Author and reference	n	Survival (%)	Prognostic factors
Raab et al. 1998 [6]	34	5-year survival: 22	Negative margins (R0), no prior local recurrence
Pocard et al. 2000 [7]	52	3-year survival: 49	Long DFI
Yoshimoto et al. 2000 [8]	25	5-year survival: 27	Not reported
Pocard et al. 2001 [9]	65	4-year survival: 46	Long DFI
Elias et al. 2003 [11]	54	5-year survival: 34	Positive hormone receptor status
Vlastos et al. 2004 [14]	31	5-year survival: 61	Not reported
Sakamoto Y et al. 2005 [15]	35	5-year survival: 31	No extrahepatic disease
Adam et al. 2006 [16]	85	5-year survival: 37	Response to preoperative chemotherapy, no R2 resection, possibility of rehepatectomy in the further course of disease
Zegarac M et al. 2013 [20]	32	Median OS 37 months	Positive hormone receptor status, negative lymph nodes, long DFI, single metastases
Weinreich 2014 [12]	21	5-year survival: 33	Negative margin (R0), low primary tumor size, negative lymph nodes, low-grade histopathology, low number of liver metastases, long DFI
Ye et al. 2015 [18]	28	5-year survival: 53 10-year survival: 33	DFI >36 months, negative margins, no tumor recurrence before metastectomy
Margonis et al. 2016 [17]	131	3-year survival: 75.2	Negative margin (R0), small diameter of the liver metastasis
Kobryn et al. 2016 [19]	30	3-year survival: 36.4	Not reported
Ercolani et al. 2005 [13] and 2018 [10]	51	5-year survival: 36 10-year survival: 16	Small tumor diameter, positive progesterone receptor status, and triple negative status

n number of patients, R residual tumor, DFI disease-free interval, n.g. not given, OS overall survival, MBC metastatic breast cancer